Anbio Biotechnology Class... (NNNN)
NASDAQ: NNNN
· Real-Time Price · USD
50.60
0.46 (0.92%)
At close: Aug 15, 2025, 10:01 AM
Company Description
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally.
It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products.
It serves over-the-counter, point-of-care testing, and laboratory markets.
The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Anbio Biotechnology Class A Ordinary Shares
| Country | DE |
| IPO Date | Feb 19, 2025 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Michael Lau |
Contact Details
Address: Wilhelm Gutbrod Str 21B Frankfurt am Main, DE | |
| Website | https://www.anbio.com |
Stock Details
| Ticker Symbol | NNNN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001982708 |
| CUSIP Number | n/a |
| ISIN Number | KYG0367B1059 |
| Employer ID | 00-0000000 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Michael Lau M.B.A., Ph.D. | Chief Executive Officer |
| Suki Song CPA | Chief Financial Officer |
| Chris Tian | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | 20-F | Filing |
| Feb 21, 2025 | 6-K | Filing |
| Feb 19, 2025 | 424B4 | Filing |
| Feb 18, 2025 | EFFECT | Filing |
| Feb 18, 2025 | CERT | Filing |
| Feb 14, 2025 | CORRESP | Filing |
| Feb 14, 2025 | CORRESP | Filing |
| Feb 14, 2025 | 8-A12B | Filing |
| Feb 10, 2025 | F-1/A | [Amend] Filing |
| Jan 24, 2025 | F-1/A | [Amend] Filing |